Strong Medicine for Bristol-Myers

The drug company will pay $499 million to settle regulatory investigations into its drug pricing and marketing activities

Bristol-Myers Squibb (BMY) said Dec. 21 that it reached a preliminary agreement to pay $499 million to settle several years of regulatory investigations into its drug pricing, sales and marketing activities.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.